- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04704791
Surgical PA-LAA Shunting: a Feasibility Study (PA-LAA)
Surgical PA-LAA Shunting for Management of Systemic Embolization in Patients With Atrial Fibrillation: a Feasibility Study
Atrial fibrillation is common and increases the risk of stroke. Traditionally patients are treated with blood thinning medications or at the time of surgery the part of the heart where blood clots form is cut out. Surgically cutting out the left atrial appendage can be difficult and complications can occur. An alternative strategy is to create a tunnel to increase blood flow and wash out the part of the heart where clots form.
This strategy has not been previously studied. The purpose of this study is to determine if creating a tunnel to increase blood flow is feasible and safe.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The goal is to understand the potential avenues to increase Left Atrial Appendage (LAA) flow in patients with Atrial Fibrillation (AF) to minimize systemic embolization risk. Flow modeling demonstrates that the anatomy of the LAA results in decreased velocities in the LAA apex. Introduction of a 3-4mm shunt in the apex can result in increased velocity, less stasis and a lower propensity for thrombus formation. Small (<8mm) inter-chamber shunts can exist in humans with no long term hemodynamic consequences in otherwise structurally normal hearts - making a strategy of pulmonary artery (PA) to LAA shunt an attractive potential therapy given anatomic proximity and gradient differential between the cardiac chambers.
This will be a 5 patient first-in-human feasibility study. The population will include patients undergoing CABG or other cardiovascular surgery with AF and a CHADS2 score >1 in whom the treating team deems traditional therapy with anticoagulants is prohibitive or ineffective (dialysis or EGFR preoperatively <15, previous bleeding with non-reversible pathology, clinically deemed contraindicated to oral anticoagulant). The intervention will be PA-LAA shunt creation at the time of surgery. As this is a single arm study there will be no comparison group.
Undersøgelsestype
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y4W7
- University of Ottawa Heart Institute
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years undergoing CV surgery
- History of AF with a CHADS2 score >1
Relative contraindication to OAC as determined by the heart team
- Dialysis or preoperative eGFR of <15
- Bleeding on DOAC/Coumadin with non-reversible pathology
- Other medical condition that makes the patient ineligible for OAC
- Anatomic proximity of LAA and PA on preoperative CT scan suitable for shunt creation
Exclusion Criteria:
- LVEF <40%
- History of VTE - either DVT or PE
- Resting baseline preoperative O2 sats <98%
- Inability of the patient to provide written informed consent
- Greater than moderate valvular heart disease which is not to be addressed during surgical intervention
- Documented mPA to PCWP <5mmHg
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Procedure arm
At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device.
The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
|
At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device.
The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Composite of device safety and performance
Tidsramme: 3 months
|
At three months feasibility will be met if there is no:
|
3 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Device related performance - maintaining patency
Tidsramme: 1 year
|
Shunt patency as assessed by TEE
|
1 year
|
Systemic embolization
Tidsramme: 1 year
|
Systemic embolization - includes stroke, TIA, MI or peripheral embolization attributable to either LAA thrombus or paradoxical embolization as clinically diagnosed by treating physician
|
1 year
|
Systemic saturations
Tidsramme: 1 year
|
Resting saturations <92% - threshold
|
1 year
|
Need for intervention to close the shunt
Tidsramme: 1 year
|
Need for intervention to close the shunt either surgically or percutaneously to
|
1 year
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 20200646-01H
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med LAA Thrombus Prevention
-
Vanderbilt University Medical CenterBoehringer IngelheimAktiv, ikke rekrutterendeAtrieflimren | Venstre atriel vedhæng Trombose | Enhedsrelateret trombe | Watchman LAA lukkeanordningForenede Stater
-
Imperative Care, Inc.RekrutteringHjerte-kar-sygdomme | Karsygdomme | Embolisme | Trombose | Tromboemboli | Akut lungeemboli | Thrombus; Embolisme | Emboli, lungeForenede Stater
-
Medical University of WarsawUkendtAtrieflimren | Atrieflimren | Ablation | Cardioversion | Transesophageal ekkokardiografi | Thrombus; EmbolismePolen
-
Bambino Gesù Hospital and Research InstituteAfsluttetSvær pædiatrisk fedme (BMI > 97° pc -Ifølge Centers for Disease Control and Prevention BMI-diagrammer-) | Ændrede leverfunktionstests | Glykæmisk intoleranceItalien
-
Coherex MedicalAfsluttetIkke-valvulær paroxysmal, vedvarende eller permanent atrieflimren | LAA Anatomi modtagelig for behandling med perkutan teknik | Antikoagulationsindikation for potentiel trombedannelse i venstre atrium
-
University Hospital, Clermont-FerrandAfsluttetKritisk pleje | Mekanisk ventilation | Tandbørstning | Ventilator Associated Pneumonia Prevention | MundplejeFrankrig
-
Second Affiliated Hospital of Nanchang UniversityIkke rekrutterer endnuAtrieflimren | Kirurgi | Thrombus; Embolisme | Warfarin | Atrielt vedhæng
-
Beijing Tsinghua Chang Gung HospitalUkendtHepatocellulært karcinom (HCC) med type III Portal Venetumor Thrombus (PVTT)Kina
Kliniske forsøg med PA-LAA shunt
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI); Pediatric Heart NetworkAfsluttetHjertefejl, medfødtForenede Stater, Canada
-
Duke UniversityPediatric Hydrocephalus Foundation; Children's Miracle Network HospitalsAfsluttetKommunikerer HydrocephalusForenede Stater
-
Boston Scientific CorporationTrukket tilbage
-
Cardia Inc.UkendtIkke-valvulær atrieflimren | Venstre atriel vedhængCanada
-
Kasr El Aini HospitalAfsluttet
-
AtriCure, Inc.Afsluttet
-
Central Clinical Hospital of the Ministry of Internal...RekrutteringAtrieflimren | Sikkerhedsproblemer | Forebyggelse af slagtilfældePolen
-
Occlutech International ABAfsluttet
-
University of GiessenAfsluttet
-
Lifetech Scientific (Shenzhen) Co., Ltd.Afsluttet